Not yet reviewed — this article is pending editorial review by Lyrea.
3-MeO-PCPr
3-MeO-PCPr is a dissociative research chemical of the arylcyclohexylamine class.citation needed It is the N-propyl homologue of 3-MeO-PCE and is reported to be slightly less potent than PCP while producing a somewhat less manic experience by comparison. As a relatively obscure research chemical, very limited data exists regarding its safety profile, pharmacology, and long-term effects. Like other arylcyclohexylamines, it may carry a risk of habit formation.1
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Available documentation of 3-MeO-PCPr is minimal and consists mainly of comparative characterization rather than detailed accounts of the experience. It is described as somewhat less potent than PCP, and as producing a less manic quality than related compounds.
See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives
Pharmacology
Pharmacodynamics
Published literature places 3-MeO-PCPr among arylcyclohexylamines perceived as ketamine-like dissociatives and believed to act predominantly through NMDA-receptor antagonism. The compound-specific study was analytical, not a clinical pharmacology study, so this is not a complete receptor profile or evidence of human efficacy. [S1][S2]2
Pharmacokinetics
The inspected analytical paper and PCP-NPS review reported no compound-specific absorption, bioavailability, distribution, metabolism, elimination, or half-life values for 3-MeO-PCPr; numerical pharmacokinetic fields should remain empty. [S1][S2]citation needed
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Dissociatives (NMDA receptor antagonists)
Harm Potential
Addiction & Dependence
Psychological
ModerateClassified as habit-forming, though specific addiction potential has not been formally characterized.
History & Culture
Online documentation
A surviving Bluelight thread dated 2 October 2011 contains a self-report and discussion of 3-MeO-PCPr. This establishes online discussion by that date, not first synthesis or first use.3
Legality
International
As of 23 August 2026, 3-MeO-PCPr (N-propyl-1-(3-methoxyphenyl)cyclohexan-1-amine) is not named or chemically designated in the current complete INCB Yellow, Green or Red Lists. The Green List instead places PCE (N-ethyl-1-phenylcyclohexylamine) and PHP/PCPy (1-(1-phenylcyclohexyl)pyrrolidine) in Schedule I and separately places 3-methoxyphencyclidine (1-(1-(3-methoxyphenyl)cyclohexyl)piperidine) in Schedule II. Those exact designations do not cover the target, which the analytical literature identifies as the 3-methoxyphenyl N-propyl compound rather than the N-ethyl, pyrrolidine or piperidine compounds. The Green List extends control to salts and applicable stereoisomers of listed substances, not to otherwise distinct N-alkyl analogues. INCB's March 2026 notice adds only MDMB-FUBINACA to Schedule II, with effect from 25 November 2026, and does not name 3-MeO-PCPr. The current INCB materials therefore establish no scheduling of 3-MeO-PCPr under the 1961, 1971 or 1988 Conventions.
By Country
ArgentinaIllegal (analog/blanket ban)
AustraliaIllegal (analog/blanket ban)
AustriaIllegal (analog/blanket ban)
CanadaIllegal (analog/blanket ban)
GermanyIllegal (analog/blanket ban)
IrelandIllegal (analog/blanket ban)
New ZealandIllegal (analog/blanket ban)
PolandIllegal (analog/blanket ban)
RussiaIllegal (analog/blanket ban)
SingaporeIllegal (analog/blanket ban)
South AfricaIllegal (analog/blanket ban)
South KoreaIllegal (analog/blanket ban)
SwitzerlandIllegal (analog/blanket ban)
United KingdomIllegal (analog/blanket ban)References
Source Pages
Citations
- Ryu IS, Kim OH, Lee YE, Kim JS, Li ZH, Kim TW, Lim RN, Lee YJ, Cheong JH, Kim HJ, Lee YS, Steffensen SC, Lee BH, Seo JW, & Jang EY. (2020). The Abuse Potential of Novel Synthetic Phencyclidine Derivative 1-(1-(4-Fluorophenyl)Cyclohexyl)Piperidine (4′-F-PCP) in Rodents. 21(13). https://doi.org/10.3390/ijms211344801
- Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, Dempster NM, & Brandt SD. (2016). Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. pubmed.ncbi.nlm.nih.gov, 8(8), 801-815. https://doi.org/10.1002/dta.1861123
- Bluelight community thread, posted 2 October 2011. bluelight.org (n.d.). https://www.bluelight.org/community/threads/3-meo-pcpr.592033/1
- Decreto 560/2019, artículo 2 y Anexo II, Grupo 2. argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-560-2019-326675/actualizacion1
- Decreto 560/2019, artículo 2 y Anexo II, Grupo 2. argentina.gob.ar (n.d.). https://www.argentina.gob.ar/sites/default/files/infoleg/326675/dec560-2.pdf1
- Criminal Code Act 1995, sections 301.1, 301.4 and 301.9; Criminal Code Regulations 2019, Schedules 1 and 2. legislation.gov.au (n.d.). https://www.legislation.gov.au/C2004A04868/2026-06-30/2026-06-30/text/original/epub/OEBPS/document_2/document_2.html1
- Criminal Code Act 1995, sections 301.1, 301.4 and 301.9; Criminal Code Regulations 2019, Schedules 1 and 2. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2019L00561/2025-12-13/2025-12-13/text/original/epub/OEBPS/document_1/document_1.html1
- Neue-Psychoaktive-Substanzen-Verordnung, Anlage II group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
- Neue-Psychoaktive-Substanzen-Verordnung, Anlage II group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/i/2011/146/P4/NOR401344471
- Controlled Drugs and Substances Act, Schedule I, item 14. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-MeO-PCPr article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
